Effect of vonoprazan fumarate on serum inflammatory factors in patients with reflux esophagitis
10.3969/j.issn.1009-0754.2024.08.017
- VernacularTitle:富马酸伏诺拉生治疗反流性食管炎对患者血清炎症因子水平的影响
- Author:
Tingting WANG
1
;
Tianqin WU
;
Xiaoxuan ZHU
;
Qing ZHU
Author Information
1. 215000 江苏苏州,苏州一〇〇医院中西医结合消化内科
- Keywords:
Vonoprazan fumarate;
Reflux esophagitis;
Inflammatory factors;
officacy
- From:
Journal of Navy Medicine
2024;45(8):853-856
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of vonoprazan fumarate on serum inflammatory factors in patients with reflux esophagitis.Methods Eighty patients with reflux esophagitis who were admitted to the Suzhou 100 Hospital from May 2021 to March 2023 were enrolled and divided into observation group(treated with vonoprazan fumarate,n=40)and control group(treated with omeprazole,n=40)according to the random number table method.The treatment efficacy,adverse reactions,Gastroesophageal Reflux Disease Questionnaire(GERDQ)score,gastrointestinal symptom score(GIS),serum gastrin(GAS),vasoactive intestinal peptide(VIP),tumor necrosis factor-α(TNF-α),interleukin(IL)-6,IL-8,and the recurrence within 6 months after treatment were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group(P<0.05).GERDQ score and GIS after treatment were lower than those before treatment in both groups,and the GERDQ score and GIS after treatment in the observation group were lower than those in the control group(all P<0.05).GAS after treatment was higher than that before treatment in both groups,and GAS after treatment in the observation group was significantly higher than that in the control group(all P<0.05).VIP,TNF-α,IL-6 and IL-8 after treatment were significantly lower than those before treatment in both groups,and after treatment these parameters in the observation group were significantly lower than those in the control group(all P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).No patients were lost during follow up.The recurrence rate was 2.50%(1/40)in the observation group and 7.50%(3/40)in the control group(χ2=0.263,P=0.608).Conclusion In treating reflux esophagitis with vonoprazan fumarate,the pharyngeal reflux,gastrointestinal hormones,and serum inflammatory factor levels can be improved,and the long-term efficacy is satisfactory.
